TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ritu Baral has given his Buy rating due to a combination of factors surrounding Benitec Biopharma’s financial and clinical progress. The company has a strong cash position of $98 million, which is projected to sustain operations through 2027. This financial stability supports the ongoing Phase 1b/2a trial and the anticipated start of a registrational trial in the second half of 2026.
Additionally, the company’s investigational therapy, BB-301, is advancing in its clinical trials for OPMD dysphagia, with promising interim data expected in the fourth quarter of 2025. The study involves both objective and subjective measures, which will provide comprehensive insights into the therapy’s efficacy. These factors, combined with strategic financial management and promising clinical data, underpin the Buy rating recommendation.
In another report released today, Citizens JMP also reiterated a Buy rating on the stock with a $20.00 price target.